David B Henley

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA
    Alzheimers Dement 8:407-16. 2012
  2. doi request reprint Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009

Collaborators

Detail Information

Publications2

  1. doi request reprint Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA
    Alzheimers Dement 8:407-16. 2012
    ..An understanding of expected rates of adverse events (AEs), overall discontinuations, and discontinuations due to AEs, serious AEs, and deaths would be useful in planning such trials...
  2. doi request reprint Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009
    ..Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit...